Physician profile
John M Ray, JR.
NPI 1134122500
$15,571.98
in general payments reported to CMS, 2019-2025
68 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $2,526 · 2021: $2,663 · 2022: $1,852 · 2023: $1,773 · 2024: $1,892 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,928.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,762.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,528.06 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Amgen INC. | $1,224.34 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,139.19 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $704.61 | 2019-2025 | |
| Abbott Laboratories | $614.56 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.75 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $502.94 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $444.23 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $420.73 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.09 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $402.64 | 2019-2022 | |
| Allergan, INC. | $382.12 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $376.76 | 2019-2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $327.40 | 2019-2021 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.